Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Filgrastim Megalabs vs Granulokine in Healthy Men
NCT04958772Phase 1Not yet recruiting
- Sponsor
- Megalabs
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Megalabs. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at 17 days, Maximum Plasma Concentration at 17 days and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04958772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958772.